Fitness, gardening, interior design
- San Diego US-CA
Fitness, gardening, interior design
A graduate of London University and London Business School, Dr. Deirdre Gillespie holds responsibilities as the president and CEO of La Jolla Pharmaceutical Company. Her memberships in medical organizations help keep her up to date with her profession. Through the British Medical Association, for example, Dr. Deirdre Gillespie remains current with news and events in the British medical community. In January 2014, the British Medical Association (BMA) announced a contest for volunteer-minded doctors to display their work - literally. The competition involves posters that showcase volunteer work that BMA doctors perform domestically in the UK as well as overseas. Medical professionals who wish to bring their volunteer work to the fore, either because the work benefited them or because they believe that the cause deserves more volunteers, are encouraged to enter. Entrants must have taken on the relevant work within the past two years. Posters that are on the short list will be displayed at the Annual Representative Meeting of the BMA in 2014. There, entrants will have the chance to promote their causes as well as their work. For more information, visit bma.org.uk.
Serving in high-level positions with such companies as La Jolla Pharmaceutical Company, Inc., and Vical, Inc., Dr. Deirdre Gillespie has overseen clinical trials, worked with investors, and ensured effective and efficient corporate governance. The chief executive officer and president of La Jolla Pharmaceutical Company, Inc., from 2006 through 2012, Dr. Deirdre Gillespie learned firsthand the importance of good corporate governance and best practice as the company transitioned to a new management team and a new board of directors. First and foremost, good corporate governance is good management: the process of distributing responsibilities to staff members to keep the business running smoothly. Second, corporate governance relies on a clear vision. Not only does this help keep policies and rules consistent for all levels of staff, but it also helps to focus the company’s objectives and clarifies the process to achieve its goals. Finally, good corporate governance must balance the needs of the stakeholders with the needs of the community. In today’s corporate world, companies are expected not only to be profitable but also to be responsible citizens.
As the former chief executive and president of La Jolla Pharmaceutical Company, Inc., Dr. Deirdre Gillespie and her team of clinical investigators conducted the largest study of systemic lupus erythematosis undertaken at that time. Over a three-year period, Dr. Deirdre Gillespie managed a process that ultimately involved testing a drug for 12 months on approximately 950 patients at dozens of sites around the world. Because clinical trials are the key in determining what effects the treatment will have on the disease and the patient, they are conducted in four controlled phases. Phase I. The first phase tests a new drug for the first time on a small group of human subjects to determine a) if it is safe; b) the safe range of dosages; and c) if there are any side effects. Phase II. This phase expands the test group to a larger group of subjects. Phase II undertakes further evaluation of safety and begins to look at effectiveness. Phase III. The third phase of testing administers the new drug to large groups and judges it against the current standard of treatment. The goals of this phase are to confirm effectiveness and to continue to monitor side effects. Phase IV. The final phase occurs after the drug has been approved by the U.S. Food and Drug Administration. Researchers monitor the results of treatment and compare them to existing treatments as well as examining the drug’s effect on the patient’s quality of life.